Also in those melanomas in which the BRAFV600E mutation determines a constitutive activation of the downstream MAPK pathway positively impacting on cell proliferation, the expression of CSPG4 is required to maximize the tumorigenic effect [52]. This evidence concerns the gene CSPG4 and melanoma.